In This Issue
10-Year APBI Data: Equivalent Outcomes, Better Cosmesis
Lit Review: APBI vs. WBI
Studies Show Excellent Outcomes with SAVI
BrachyBytes Editorial Advisory Board

Robert Kuske, M.D.

Jay Reiff, Ph.D.
Dan Scanderbeg, Ph.D.
Catheryn Yashar, M.D.
Vic Zannis, M.D.
Upcoming Events

 


ABS Breast Brachytherapy School 

October 24-25, 2013
Mandarin Oriental
Las Vegas, NV

San Antonio Breast Cancer Symposium
December 10-14, 2013

Henry B. Gonzalez Convention Center
San Antonio, TX
Website

Become a Center of Excellence in APBI

Learn about becoming a Center of Excellence and find ways to grow your APBI program by reaching out to referring physicians and women in the community.

Contact info@ciannamedical.com for more information.  
Follow-up Links

Past Issues
Cianna Medical

BEST Forum
SAVI Sisters

Virginia Hospital Center
Breast Cancer Symposium
ASTRO

September 2013 

10-Year APBI Data: Equivalent Outcomes, Better Cosmesis 
Robert Hong, MD  

As acceptance of accelerated partial breast irradiation (APBI) continues to grow, so does the body of evidence supporting its equivalence to whole breast irradiation (WBI).

Most recently, researchers from Hungary published 10-year data from a randomized clinical trial comparing the outcomes of breast conservation therapy (BCT) with APBI versus conventional WBI. Not only did the researchers observe no adverse effect on local control or survival, but they also reported significantly better cosmetic results with the use of APBI.

Radiation oncologist Robert Hong, MD, of Virginia Hospital Center in Arlington, Va., discusses the results of the Hungarian trial, how it compares to his own clinical experience with APBI, and what the data means for the future of early-stage breast cancer treatment.

Read more

Literature Review: APBI vs. WBI

Researchers continue to add to the growing literature comparing the efficacy and long-term clinical outcomes of patients treated with APBI vs. WBI, including:

Polgar C, et al.
National Institute of Oncology, Budapest, Hungary

Radiother Oncol (2013)

Wobb J, et al.
Beaumont Cancer Institute, Royal Oak, MI

Presented at 2013 Breast Cancer Symposium

Shah C, et al.
William Beaumont Hospital, Royal Oak, MI
Radiother Oncol (2011)

Studies Show Excellent Outcomes with SAVI

Several studies presented at medical conferences this month showed excellent outcomes with the SAVI® breast brachytherapy applicator, including low recurrence rates, few toxicities, excellent cosmetic outcomes and high rates of survival. The data came from the SAVI Collaborative Research Group (SCRG), which was established to study the long-term outcomes of women receiving APBI with SAVI. Read more

  • At the Breast Cancer Symposium, researchers presented the largest reported series to date of of DCIS patients treated with SAVI. With 284 patients and more than 2 years of follow-up, researchers noted excellent local control (1.4% recurrence rate) and low toxicity. View poster

At the 55th annual ASTRO meeting:

  • A study of 101 patients detailed outcomes with the most mature follow-up of patients treated with SAVI (4.5 years), reporting very low toxicity rates (< 3%) and excellent local control (98%). Overall and cause-specific actuarial survival rates were 100%.  View poster
    • A study of 576 patients with a median follow-up of 3 years showed similarly low toxicities and a local recurrence rate of less than 2.5%. Overall and cause-specific actuarial survival rates were 99.5%. View poster

 

  • A third study analyzed the radiation treatment plans for over 1,000 patients. The data demonstrated SAVI’s flexibility in shaping the radiation dose, which researchers concluded protects critical structures and makes brachytherapy an option for patients who would not be candidates for other single-entry devices. View poster